Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels

Abstract:

Methods: Evinacumab 10 or 500 mg/L was added to whole blood collected from healthy volunteers and subjected to lipid-apheresis (Kaneka LIPOSORBER® system). Total ANGPTL3 and evinacumab were measured in plasma samples (n= 7) using ELISA. Ex-vivo data were compared with phase 3 trial data (NCT03399786), in which 22 HoFH patients (placebo [n= 8]; evinacumab [n= 14]) underwent lipid-apheresis. Results: In post-apheresis ex-vivo plasma samples, evinacumab levels were reduced by 20±9% and ANGPTL3 levels were reduced by 20±13%(results for both doses combined). Based on clinical data from the subsequent phase 3 study, serum concentrations of evinacumab immediately after lipid-apheresis were, on average,∼ 20% lower than those immediately prior to lipid-apheresis. As this magnitude of difference is within the ranges of intra-patient and inter-patient variability in evinacumab …

Año de publicación:

2020

Keywords:

Fuente:

google